Resources » von Willebrand Disease | WFH World Congress 2022

Year: 2022

Language: English

This resource is also available in: French Spanish

Author(s): World Federation of Hemophilia

Format: Congress recordings

von Willebrand Disease | WFH World Congress 2022


In these sessions from the WFH 2022 World Congress, listen to Peter Lenting, Magdy El Ekiaby, Nathan Connell, Brooke Sadler, Giancarlo Castaman, James O’Donnell, Baiba Ziemele, Veronica Flood, Paula James and Helen Campbell address current topics in von Willebrand Disease.

The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

In this plenary from the WFH 2022 World Congress, Peter Lenting (France) was presented with the Arosenius award and discussed novel therapeutic strategies in VWD. His presentation included the use of the bispecific antibody emicizumab in the treatment of VWD-type 3 and the aptamer BT200 to increase levels of the VWF/FVIII complex, as well as present novel approaches based on the use of synthetic molecules and single-domain antibodies, both of which being at the preclinical discovery stage.

In this session from the WFH 2022 World Congress, Magdy El Ekiaby (Egypt), Nathan Connell (United States), Brooke Sadler (United States), Giancarlo Castaman (Italy) and James O’Donnell (Ireland), discuss how in the past several decades, knowledge of the underlying pathogenesis of von Willebrand disease (VWD) has increased tremendously, thanks in no small part to detailed genetic mapping of the von Willebrand Factor (VWF) gene and advances in genetic and bioinformatic technology. However, these advances do not always easily translate into improved management for patients with VWD and low-VWF levels. The presenters in this session will review VWD within and outside of VWF; pregnancy management in women with VWD; and the role of the VWF/ADAMTS-13 axis in COVID-19 infection.

In this session from the WFH 2022 World Congress, Baiba Ziemele (Latvia), Veronica Flood (United States), Paula James (Canada) and Helen Campbell (United Kingdom) will take a closer look into how von Willebrand Disease (VWD) is perceived worldwide and the treatment options that now exist. It will also give the perspective of a person who lives with VWD, and how it differs between men and women.